Data on Colon Cancer Reported by Researchers at Tokyo University of Science (Association between Low-Dose Aspirin Use and Colorectal Cancer Incidence Using Japanese Large-Scale Health Insurance Claims Data): Oncology – Colon Cancer

2026 JUL 09 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Researchers detail new data in Oncology - Colon Cancer. According to news reporting from Tokyo, Japan, by NewsRx journalists, research stated, “Although experimental studies suggest that low-dose aspirin has chemopreventive effects against colorectal cancer, clinical evidence remains inconsistent, and studies on Japanese populations are limited. This study aimed to evaluate the relationship between low-dose aspirin and colorectal cancer using a large-scale Japanese database.”

Financial supporters for this research include Japan Agency for Medical Research and Development, Japan Agency for Medical Research and Development, Japan Agency for Medical Research and Development, Ministry of Education, Culture, Sports, Science and Technology, Ministry of Education, Culture, Sports, Science and Technology.

The news correspondents obtained a quote from the research from the Tokyo University of Science, “A nested case-control study was conducted using a health insurance claims database (2005-2021). Cases were defined as patients with a diagnosis of colorectal cancer during the study period, with the month of the first diagnosis as the index month, and were matched 1:4 risk-set sampling with population controls based on age and sex. Exposure was defined as the use of low-dose aspirin prior to the index month. We further analyzed recency and duration. Recency was categorized as recent use (<3 months before the index month) and past use ( 3 months before the index month). Duration was classified into two groups: <2 years and 2 years. In total, 17,373 cases and 69,492 controls were included. Conditional logistic regression analysis, adjusted for patient background, showed that low-dose aspirin use may reduce the risk of colorectal cancer (adjusted odds ratio: 0.87; 95% confidence interval, 0.79-0.97). For recency and duration, the risk of colorectal cancer was significantly reduced by recent use and 2 years compared with never use. Low-dose aspirin use may be associated with a reduced risk of colorectal cancer.”

According to the news reporters, the research concluded: “These findings contribute to the clinical evidence regarding colorectal cancer prevention in Asian populations.”

This research has been peer-reviewed.

For more information on this research see: Association between Low-Dose Aspirin Use and Colorectal Cancer Incidence Using Japanese Large-Scale Health Insurance Claims Data. Cancer Epidemiology, Biomarkers & Prevention, 2026;35(7):1182-1188. Cancer Epidemiology, Biomarkers & Prevention can be contacted at: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA.

Our news journalists report that additional information may be obtained by contacting Karin Ono, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan. Additional authors for this research include Ayako Maeda-Minami, Hideki Ishikawa, Michihiro Mutoh and Yasunari Mano.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1158/1055-9965.epi-25-2015. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal Cancer Epidemiology, Biomarkers & Prevention is: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)